References
1. Greene AK, Perlyn CA, Alomari AI. Management of lymphatic
malformations. Clin Plast Surg . Jan 2011;38(1):75-82.
doi:10.1016/j.cps.2010.08.0062. Kulungowski AM, Patel M. Lymphatic
malformations. Semin Pediatr Surg . Oct 2020;29(5):150971.
doi:10.1016/j.sempedsurg.2020.1509713. Nguyen HL, Bonadurer GF, 3rd,
Tollefson MM. Vascular Malformations and Health-Related Quality of Life:
A Systematic Review and Meta-analysis. JAMA Dermatol . Jun 1
2018;154(6):661-669. doi:10.1001/jamadermatol.2018.00024. Adams DM,
Trenor CC, 3rd, Hammill AM, et al. Efficacy and Safety of Sirolimus in
the Treatment of Complicated Vascular Anomalies. Pediatrics . Feb
2016;137(2):e20153257. doi:10.1542/peds.2015-32575. Karar J, Maity A.
PI3K/AKT/mTOR Pathway in Angiogenesis. Front Mol Neurosci .
2011;4:51. doi:10.3389/fnmol.2011.000516. Uebelhoer M, Boon LM, Vikkula
M. Vascular anomalies: from genetics toward models for therapeutic
trials. Cold Spring Harb Perspect Med . Aug 1
2012;2(8)doi:10.1101/cshperspect.a0096887. Venot Q, Blanc T, Rabia SH,
et al. Targeted therapy in patients with PIK3CA-related overgrowth
syndrome. Nature . Jun 2018;558(7711):540-546.
doi:10.1038/s41586-018-0217-98. Canaud G, Lopez Gutierrez JC, Irvine AD,
et al. Alpelisib for treatment of patients with PIK3CA-related
overgrowth spectrum (PROS). Genet Med . Dec 2023;25(12):100969.
doi:10.1016/j.gim.2023.1009699. Triana P, Lopez-Gutierrez JC. Activity
of a TIE2 inhibitor (rebastinib) in a patient with a life-threatening
cervicofacial venous malformation. Pediatr Blood Cancer . Aug
2023;70(8):e30404. doi:10.1002/pbc.3040410. Edwards EA, Phelps AS, Cooke
D, et al. Monitoring Arteriovenous Malformation Response to
Genotype-Targeted Therapy. Pediatrics . Sep
2020;146(3)doi:10.1542/peds.2019-320611. Adler F, Gupta N, Hess CP, Dowd
CF, Dillon WP. Intraosseous CSF fistula in a patient with Gorham disease
resulting in intracranial hypotension. AJNR Am J Neuroradiol . Dec
2011;32(11):E198-200. doi:10.3174/ajnr.A241312. Apsel Winger B, Devine
WP, Hsiao EC, et al. EML4::ALK fusions in complex lymphatic
malformations. Pediatr Blood Cancer . Jun 28 2023:e30516.
doi:10.1002/pbc.3051613. Horn L, Pao W. EML4-ALK: honing in on a new
target in non-small-cell lung cancer. J Clin Oncol . Sep 10
2009;27(26):4232-5. doi:10.1200/JCO.2009.23.666114. Mano H. Non-solid
oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.Cancer Sci . Dec 2008;99(12):2349-55.
doi:10.1111/j.1349-7006.2008.00972.x15. Soda M, Choi YL, Enomoto M, et
al. Identification of the transforming EML4-ALK fusion gene in
non-small-cell lung cancer. Nature . Aug 2 2007;448(7153):561-6.
doi:10.1038/nature0594516. Sozzi G, Martelli MP, Conte D, et al. The
EML4-ALK transcript but not the fusion protein can be expressed in
reactive and neoplastic lymphoid tissues. Haematologica . Sep
2009;94(9):1307-11. doi:10.3324/haematol.2009.00804517. Antonescu CR,
Suurmeijer AJ, Zhang L, et al. Molecular characterization of
inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene
fusions and rare novel RET rearrangement. Am J Surg Pathol . Jul
2015;39(7):957-67. doi:10.1097/PAS.000000000000040418. Sokai A, Enaka M,
Sokai R, et al. Pulmonary inflammatory myofibroblastic tumor harboring
EML4-ALK fusion gene. Jpn J Clin Oncol . Jan 2014;44(1):93-6.
doi:10.1093/jjco/hyt17319. Soda M, Takada S, Takeuchi K, et al. A mouse
model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S
A . Dec 16 2008;105(50):19893-7. doi:10.1073/pnas.080538110520. Malik
SM, Maher VE, Bijwaard KE, et al. U.S. Food and Drug Administration
approval: crizotinib for treatment of advanced or metastatic non-small
cell lung cancer that is anaplastic lymphoma kinase positive. Clin
Cancer Res . Apr 15 2014;20(8):2029-34.
doi:10.1158/1078-0432.CCR-13-307721. Choi YL, Soda M, Yamashita Y, et
al. EML4-ALK mutations in lung cancer that confer resistance to ALK
inhibitors. N Engl J Med . Oct 28 2010;363(18):1734-9.
doi:10.1056/NEJMoa100747822. Katayama R, Shaw AT, Khan TM, et al.
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung
Cancers. Sci Transl Med . Feb 8 2012;4(120):120ra17.
doi:10.1126/scitranslmed.300331623. Giunta EF, Signori A, West HJ, et
al. Beyond Crizotinib: A Systematic Review and Meta-Analysis of the
Next-Generation ALK Inhibitors as First-Line Treatment for
ALK-Translocated Lung Cancer. Front Oncol . 2022;12:921854.
doi:10.3389/fonc.2022.92185424. Shaw AT, Bauer TM, de Marinis F, et al.
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung
Cancer. N Engl J Med . Nov 19 2020;383(21):2018-2029.
doi:10.1056/NEJMoa2027187